| Parathyroid hormone and parathyroid hormone related protein assays in the investigation of hypercalcemic patients in hospital in a Chinese population. | |
| | |
MedLine Citation:
|
PMID: 9309539 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
There are many pathological causes and potential mechanisms for hypercalcemia. We measured intact parathyroid hormone (PTH) and parathyroid hormone related protein (PTHrP) in the hypercalcemic in-patients and attempted to evaluate the roles of PTH and PTHrP in hypercalcemia due to malignancy. We performed a prospective study of 178 patients with corrected serum calcium concentrations greater than 2.74 mmol/l in a hospital over a 3-year period. We measured calcium and albumin using a Hitachi 747 autoanalyzer, and we measured PTH and PTHrP by two-site immunoradiometric assays (IRMA). Hypercalcemia was attributed to malignancy alone in 93 patients (52.3%), primary hyperparathyroidism (HPT) alone in 28 patients (15.7%), uremia with hemodialysis in 23 patients (12.9%), unknown in 16 patients (9%), primary HPT coexisting with malignancy in 7 patients (3.9%) and other rare causes (6.2%). Plasma PTHrP levels were elevated in 71/93 (76.3%) patients with hypercalcemia due to malignancy, but the elevated PTHrP percentage differed for each kind of tumor. PTHrP levels were elevated in 100% of patients with squamous carcinomas (CA) in the lung, esophagus, skin, cholangiocarcinoma of liver, and breast CA. The positive bony metastatic rate was 44.1% (41/93). There was no correlation between high PTHrP and bony metastasis. There was a good correlation between the corrected serum calcium and PTHrP levels (r = 0.476, p < 0.001), but no correlation between survival time and serum calcium level or PTHrP level. There was no significant difference in life expectancy after cancer diagnosis between the high PTHrP group and normal PTHrP group, and there was no significant difference in life expectancy after the first occurrence of hypercalcemia between the two groups. Measurement of both PTH and PTHrP levels led to a change in the initial diagnosis in 7 patients. In routine practice, measurement of serum PTH alone is not enough. This study suggests that the appropriate combination of PTH and PTHrP assays results in a more accurate diagnosis of the hypercalcemic causes. In addition, especially high PTHrP levels should be screened for malignancy. However, the prognosis in cancer patients after hypercalcemia with high PTHrP group, as compared to those with the normal PTHrP group is not significantly different. |
| | |
Authors:
|
J K Lee; M J Chuang; C C Lu; L J Hao; C Y Yang; T M Han; H C Lam |
Related Documents
:
|
11076109 - Detection and quantification of cardiovascular calcifications with electron beam tomogr... 8678959 - Values of ultrasonography, sestamibi scintigraphy, and intraoperative measurement of 1-... 17130879 - Vitamin d replacement for cirrhosis-related bone disease. 2730299 - Active metabolites of vitamin d in patients with coxarthrosis and with aseptic loosenin... 7973919 - Adolescents having obesity surgery: a 6-year follow-up. 1985539 - Locally recurrent parathyroid neoplasms as a cause for recurrent and persistent primary... 21868619 - The depth of the olfactory sulcus is an indicator of congenital anosmia. 12767549 - Subclinical skeletal muscle abnormalities in patients with hypertrophic cardiomyopathy ... 7087849 - Incidence and causes of hyperbilirubinaemia in a hospital population: with particular r... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of endocrinological investigation Volume: 20 ISSN: 0391-4097 ISO Abbreviation: J. Endocrinol. Invest. Publication Date: 1997 Jul-Aug |
Date Detail:
|
Created Date: 1997-10-30 Completed Date: 1997-10-30 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7806594 Medline TA: J Endocrinol Invest Country: ITALY |
Other Details:
|
Languages: eng Pagination: 404-9 Citation Subset: IM |
Affiliation:
|
Department of Medicine, Veterans General Hospital-Kaohsiung, Taipei, Taiwan, Republic of China. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Bone Neoplasms / secondary Calcium / blood Female Humans Hypercalcemia / blood*, etiology Hyperparathyroidism / complications Immunoradiometric Assay Male Middle Aged Neoplasms / complications Parathyroid Hormone / blood* Parathyroid Hormone-Related Protein Prospective Studies Proteins / analysis* Reference Values Renal Dialysis Taiwan Uremia / complications, therapy |
| Chemical | |
Reg. No./Substance:
|
0/PTHLH protein, human; 0/Parathyroid Hormone; 0/Parathyroid Hormone-Related Protein; 0/Proteins; 7440-70-2/Calcium |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Role of 17-beta-estradiol and progesterone on glucose homeostasis: effects of food restriction (50%)...
Next Document: Role of serotoninergic receptors in gonadotropin secretion in male rats.